| 0.4066 -0.044 (-9.66%) | 10-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.73  |
1-year : | 0.89 |
| Resists | First : | 0.62 |
Second : | 0.76 |
| Pivot price | 0.52 |
|||
| Supports | First : | 0.4 |
Second : | 0.33 |
| MAs | MA(5) : | 0.47 |
MA(20) : | 0.55 |
| MA(100) : | 0.72 |
MA(250) : | 0.97 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 19.1 |
D(3) : | 24.5  |
| RSI | RSI(14): 29.8 |
|||
| 52-week | High : | 2.44 | Low : | 0.37 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GUTS ] has closed below the lower bollinger band by 0.4%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 8.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.45 - 0.45 | 0.45 - 0.46 |
| Low: | 0.39 - 0.4 | 0.4 - 0.4 |
| Close: | 0.4 - 0.41 | 0.41 - 0.41 |
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Fri, 02 Oct 2026
Fractyl Health, Inc. (GUTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Thu, 01 Oct 2026
Lost Money on Fractyl Health, Inc. (GUTS)? Join Class Action Before October 20, 2026 - Contact Levi & Korsinsky - ACCESS Newswire
Thu, 01 Oct 2026
Bragar Eagel & Squire, P.C. Urges Fractyl Health, Inc. - GlobeNewswire
Wed, 30 Sep 2026
GUTS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Wed, 30 Sep 2026
Fractyl Health, Inc. (GUTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Wed, 30 Sep 2026
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 20, 2026 in Fractyl Health, Inc. Lawsuit - GUTS - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 159 (M) |
| Shares Float | 146 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 51.5 (%) |
| Shares Short | 2,660 (K) |
| Shares Short P.Month | 2,520 (K) |
| EPS | -0.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.01 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -74.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -82 (M) |
| Levered Free Cash Flow | -48 (M) |
| PE Ratio | -0.45 |
| PEG Ratio | 0 |
| Price to Book value | -40.66 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|